AKTS — Aktis Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $1.09bn
- $547.77m
- $6.50m
Annual cashflow statement for Aktis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -17.9 | -28.6 | -44 | -63.7 |
| Depreciation | ||||
| Non-Cash Items | 0.498 | -2.73 | -2.67 | 1.54 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -1.14 | 0.242 | 59.8 | -4.27 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -18.1 | -30 | 14.8 | -64.1 |
| Capital Expenditures | -2.31 | -3.76 | -2.86 | -9.58 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0 | -65.1 | -188 | 75.5 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -2.31 | -68.8 | -190 | 66 |
| Financing Cash Flow Items | -0.151 | 0 | -1.9 | -1.55 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 120 | 0 | 183 | -1.21 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 99.6 | -98.8 | 7.65 | 0.625 |